Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FGFR3 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B
FGFR3 mutation	Cholangiocarcinoma	FGFR3 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Gastric Cancer	FGFR3 mutation	Gastric Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Solid Tumor	FGFR3 mutation	Solid Tumor	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Bladder Cancer	FGFR3 mutation	Bladder Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR3 mutation	Bladder Cancer	FGFR3 mutation	Bladder Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 mutation	Breast Cancer	FGFR3 mutation	Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR3 mutation	Solid Tumor	FGFR3 mutation	Solid Tumor	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2